# ICG PERSPECTIVECHALLENGES AND WORKPLAN FOR ORAL CHOLERA VACCINE EMERGENCY STOCKPILE

Dr Mohammad Salim Reza
ICG Secretariat, 11 October 2022





#### **ICG** mandate

- The core mandate of the ICG is to make available and ensure equitable access to licensed vaccines for cholera, meningitis, yellow fever, and Ebola virus disease during outbreaks.
- The ICG mechanism seeks to ensure timely and targeted deployment so that vaccines can be used as effective tools to control outbreaks where they are most needed.






#### Achievements- OCV emergency stockpile

VACCINE DOSES SHIPPED BY COUNTRY: 2016 - 2022

Doses Shipped (2016-2022)-55,130,922

**Countries-20** 



#### Disclaimer

The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.




© WHO 2022. All rights reserved.





#### Achievements- OCV emergency stockpile








#### OCV Doses Requested & Approved 2017-2022

High Demand




■ Doses requested ■ Doses Approved

\*2022- until September






High Demand







High Demand






A green arrow represents an ICG request for which the number of doses approved were adjusted given the limited OCV supply at that moment.



High Demand





A green arrow represents an ICG request for which the number of doses approved were adjusted given the limited OCV supply at that moment.



#### Some solutions to face high

#### domand /low outpalv

- Increasing stockpile size (next slide)
- ICG approvals for 2-round campaigns, but for not affecting the supply:
  - Only doses for 1<sup>st</sup> round are shipped.
  - Doses for 2<sup>nd</sup> round are conditional to submission of campaign report of 1<sup>st</sup> round, OCV availability at the moment, and potential demand (ongoing outbreaks and ICG requests in the pipeline)
- Partial approval of some requests.





#### Some solutions to face high

#### damand llaw aunahy

- ICG annual meeting, Sept 2018:
  - The ICG members decided to increase the OCV emergency stockpile size from 2 to 3 million doses available at all times, effective from 2019.

- ICG annual meeting, Sept 2021:
  - Considering the increased OCV demand and limited OCV supply, the ICG members decided to increase the emergency stockpile size from 3 to 5 million doses available at all times, effective from 2022.






#### **Total number of days for Vaccine arrival in**

## Delay in Vaccine arrival (average 16 days)

- Availability of cargo flights
- Cold chain capacity in the country
- Obtaining green lights from the country



\*indicates the duration from decision taken by ICG to the shipment arrival in country






#### Total number of days to start campaign after vaccine

# Late in campaign implementation (average 29 days)

- Operational issue
- Funding
- Priority over other diseases
- Security
- Remoteness







## ICG workplan for OCV (2022-2023)

Updating ICG OCV request form and annexes

• Simpler, user-friendly

OpenWHO trainings on ICG mechanism and guideline to fill up the ICG request form

Capacity building of stakeholders, on-site trainings in high priority countries.


Organize 3-level technical call, meeting with ICG members and country team as appropriate

Partners' engagementcoordinate with ICG members for field support




#### For more information:

https://www.who.int/groups/icg/cholera



https://openwho.org/courses/introduction-icg-and-mechanism







## Thank you!





